MDR1 inhibition increases sensitivity to doxorubicin and etoposide in adrenocortical cancer.
Chemotherapy for adrenocortical carcinoma (ACC) has limited efficacy and is accompanied by severe toxicity. This lack of effectiveness has been associated with high tumoral levels of the multidrug resistance (MDR) pump P-glycoprotein (P-gp), encoded by the MDR1 gene. In this study, effects of P-gp inhibition on sensitivity of ACC cells to cytotoxic drugs were evaluated. MDR1 mRNA and P-gp expression were determined in human adrenal tissues and cell lines. H295R, HAC15, and SW13 cells were treated with mitotane, doxorubicin, etoposide, cisplatin, and streptozotocin, with or without the P-glycoprotein inhibitors verapamil and tariquidar. Cell growth and surviving fraction of colonies were assessed. MDR1 mRNA and P-gp protein expression were lower in ACCs compared to adrenocortical adenomas (P<0.0001; P<0.01, respectively). MDR1 and P-gp expression were positively correlated in ACC (P<0.0001, ρ = 0.723). Mitotane, doxorubicin, cisplatin, and etoposide dose-dependently inhibited cell growth in H295R, HAC15, and SW13. Tariquidar, and in H295R also verapamil, increased the response of HAC15 and H295R to doxorubicin (6.3 and 7.5 fold EC50 decrease in H295R, respectively; all P<0.0001). Sensitivity to etoposide was increased in H295R and HAC15 by verapamil and tariquidar (all P<0.0001). Findings were confirmed when assessing colony formation. We show that cytotoxic drugs, except streptozotocin, used for ACC treatment, inhibit ACC cell growth and colony formation at clinically achievable concentrations. P-gp inhibition increases sensitivity to doxorubicin and etoposide, suggesting that MDR1 is involved in sensitivity to these drugs and could be a potential target for cytotoxic treatment improvement in ACC.